DMPS can reverse the features of severe mercury vapor-induced neurological damage

Clin Toxicol (Phila). 2009 Nov;47(9):894-8. doi: 10.3109/15563650903333812.

Abstract

Case report: A 36-year-old jewelry producer presented with tremor, slurred speech, lethargy, headache, and incoordination. On examination he had a coarse tremor of the outstretched hands and protruded tongue, slurred speech, "Hatter's shakes" handwriting, impaired heel-toe walking and heel-shin coordination, mild dysdiadochokinesis, and constricted visual fields to confrontation. The patient received four 5-day courses of oral 2,3-dimercapto-1-propanesulfonate (30 mg/kg/day), which was associated with substantial objective clinical improvement and the excretion of 99,406 microg mercury.

Conclusion: We recommend that the administration of 2,3-dimercapto-1-propanesulfonate should be considered in symptomatic patients who have been exposed to mercury vapor and who have supporting analytical confirmation of the diagnosis.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Adult
  • Antidotes / therapeutic use*
  • Chelating Agents / therapeutic use*
  • Humans
  • Inhalation Exposure / adverse effects
  • Jewelry
  • Male
  • Mercury Poisoning / drug therapy*
  • Mercury Poisoning / physiopathology
  • Occupational Exposure / adverse effects
  • Severity of Illness Index
  • Treatment Outcome
  • Unithiol / therapeutic use*

Substances

  • Antidotes
  • Chelating Agents
  • Unithiol